Qingtao Jiang1, Yun Sun2, Xin Liu3. 1. a Department of Medicine, Jiangsu Health Vocational College , Nanjing , China. 2. b Center for Disease Prevention and Control of Changzhou , Changzhou , China. 3. c Institute of Occupational Disease Prevention, Jiangsu Provincial Center for Disease Prevention and Control , Nanjing , China.
Abstract
Background: CXCR4 is a member of the C-X-C chemokine receptor family, which is associated with multiple types of cancer. Although it has been widely reported, the prognostic value of CXCR4 expression in gastrointestinal (GI) cancer remains controversial. Methods: A meta-analysis was conducted to investigate the relationship between CXCR4 and prognosis of patients with GI cancer. Subgroup analysis was also performed according to tumour subtypes and heterogeneity test. Results: A total of 24 studies including 3637 cases suggested that overexpression of CXCR4 is significantly associated with overall survival (OS) for patients with GI cancer (HR = 1.71, 95% CI = 1.45-2.03, p = 0.000). Subgroup analysis also indicated that high CXCR4 expression in oesophagus, gastric and colorectal cancer all predicted a worse prognosis (HR = 1.52, 95% CI = 1.26-1.84, p = 0.001 for oesophagus cancer; HR = 1.59, 95% CI = 1.10-2.30, p = 0.015 for gastric cancer; HR = 2.21, 95% CI = 1.56-3.14, p = 0.000 for colorectal cancer). Conclusions: CXCR4 may serve as a prognostic indicator in GI cancer patients.
Background: CXCR4 is a member of the C-X-C chemokine receptor family, which is associated with multiple types of cancer. Although it has been widely reported, the prognostic value of CXCR4 expression in gastrointestinal (GI) cancer remains controversial. Methods: A meta-analysis was conducted to investigate the relationship between CXCR4 and prognosis of patients with GI cancer. Subgroup analysis was also performed according to tumour subtypes and heterogeneity test. Results: A total of 24 studies including 3637 cases suggested that overexpression of CXCR4 is significantly associated with overall survival (OS) for patients with GI cancer (HR = 1.71, 95% CI = 1.45-2.03, p = 0.000). Subgroup analysis also indicated that high CXCR4 expression in oesophagus, gastric and colorectal cancer all predicted a worse prognosis (HR = 1.52, 95% CI = 1.26-1.84, p = 0.001 for oesophagus cancer; HR = 1.59, 95% CI = 1.10-2.30, p = 0.015 for gastric cancer; HR = 2.21, 95% CI = 1.56-3.14, p = 0.000 for colorectal cancer). Conclusions: CXCR4 may serve as a prognostic indicator in GI cancerpatients.
Authors: Philipp Linde; Christian Baues; Simone Wegen; Maike Trommer; Alexander Quaas; Johannes Rosenbrock; Eren Celik; Simone Marnitz; Christiane J Bruns; Thomas Fischer; Klaus Schomaecker; Hans-Juergen Wester; Alexander Drzezga; Lutz van Heek; Carsten Kobe Journal: Cancer Imaging Date: 2021-02-12 Impact factor: 3.909